The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer


Yildiz R., Benekli M., Buyukberber S., Kaya A. O. , Ozturk B., Yaman E., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.136, ss.1471-1476, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 136 Konu: 10
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1007/s00432-010-0803-1
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.1471-1476

Özet

Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients.